Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an injection for intravenous use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in acute heart failure settings. Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion. Cardiogenic shock (off‑label): supports myocardial contractility when conventional therapy is insufficient. Post‑cardiac surgery low cardiac output syndrome: improves hemodynamics and facilitates weaning from mechanical support.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate during therapy.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Severe hypotension: profound blood pressure drop requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan requires careful monitoring and specific safety measures. - Blood pressure monitoring: observe for hypotension during and after infusion. - Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders. - Renal impairment adjustment: consider dose modification in severe renal dysfunction. - Hepatic dysfunction caution: use with caution in patients with significant liver disease. - Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concomitant vasodilators (e.g., nitroglycerin): may cause additive hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma levels. - Other calcium sensitizers: risk of excessive inotropic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate volume depletion and hypotension. - Beta‑blockers: may blunt desired chronotropic response. - ACE inhibitors or ARBs: require blood pressure monitoring for additive effects.